{"schema_version":"secwatch.filing_event.v1","accession":"0001746473-24-000073","form_type":"8-K","ticker":"PLRX","cik":"0001746473","company_name":"PLIANT THERAPEUTICS, INC.","filed_at":"2024-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.868549+00:00","generated_at":"2026-06-02T22:15:37.229006+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Pliant Therapeutics Q1 net loss $47.0M; bexotegrast adaptive Phase 2b/3 accelerated","bullets":["Net loss $47.0M in Q1 2024 vs $37.5M in Q1 2023; R&D expenses rose to $37.1M from $29.3M.","BEACON-IPF Phase 2b/3 adaptive design upsized to 360 patients; enrollment completion expected Q1 2025.","Phase 2a PET imaging trial completed; topline data on total lung collagen and FVC expected in weeks.","Oxford loan facility upsized by $50M to $150M; $30M drawn. Cash $483.9M funded through 2026.","Regulatory clearance for PLN-101325 Phase 1 in muscular dystrophy; Phase 1 of PLN-101095 in solid tumors ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0001746473-24-000073","json":"https://secwatch.observer/filing/0001746473-24-000073.json","markdown":"https://secwatch.observer/filing/0001746473-24-000073.md","text":"https://secwatch.observer/filing/0001746473-24-000073.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1746473/000174647324000073/0001746473-24-000073-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1746473/000174647324000073/plrx-20240506.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T22:15:37.229006+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"66fd73c50ca688d5f2f90216f873507be0aea7fa","claim":"PLIANT THERAPEUTICS, INC. reported first quarter ended March 31, 2024 results: net income Net loss of $47.0 million.","evidence_excerpt":"Pliant Therapeutics, Inc. (the \"Company\") issued a press release announcing the Company’s financial results for the first quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1746473/000174647324000073/0001746473-24-000073-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Net income","value":"Net loss of $47.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}